Healthcare | October 23, 2022
IHL Launches Heart Health Calculator
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
The ANDA was filed as 'First to File' submission on NCE-1 date.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Subscribe To Our Newsletter & Stay Updated
